Literature DB >> 23052340

[Pathogenesis of diabetes mellitus and diabetic complications. Studies on diabetic mouse models].

N Herbach1.   

Abstract

Diabetic mouse models created via random mutagenesis or genetic modification are essential tools to unravel the mechanisms involved in the development of diabetes mellitus and associated diseases. Three diabetic mutant mouse lines derived from the Munich N-ethyl-N-nitrosourea (ENU) mouse mutagenesis project and one transgenic mouse line were analyzed with respect to diabetes-relevant clinical, pathomorphological and therapeutic aspects. An Ins2 mutation and two Gck mutations were identified as the cause of diabetes mellitus in the mutant lines. Heterozygous Ins2 and homozygous Gck mutants serve as model for permanent neonatal diabetes mellitus (PNDM) and heterozygous Gck mutants develop maturity onset diabetes of the young type 2. Dominant-negative glucose-dependent insulinotropic polypeptide receptor (GIPR(dn)) transgenic mice exhibit defective postnatal islet growth, develop PNDM and progressive diabetes-associated kidney lesions. The mutant and transgenic diabetic mouse models analyzed in the study were shown to represent valuable models to study the pathogenesis of monogenic diabetes and to establish novel treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23052340     DOI: 10.1007/s00292-012-1637-1

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  16 in total

1.  The clinical-chemical screen in the Munich ENU Mouse Mutagenesis Project: screening for clinically relevant phenotypes.

Authors:  B Rathkolb; T Decker; E Fuchs; D Soewarto; C Fella; S Heffner; W Pargent; R Wanke; R Balling; M Hrabé de Angelis; H J Kolb; E Wolf
Journal:  Mamm Genome       Date:  2000-07       Impact factor: 2.957

2.  Genome-wide, large-scale production of mutant mice by ENU mutagenesis.

Authors:  M H Hrabé de Angelis; H Flaswinkel; H Fuchs; B Rathkolb; D Soewarto; S Marschall; S Heffner; W Pargent; K Wuensch; M Jung; A Reis; T Richter; F Alessandrini; T Jakob; E Fuchs; H Kolb; E Kremmer; K Schaeble; B Rollinski; A Roscher; C Peters; T Meitinger; T Strom; T Steckler; F Holsboer; T Klopstock; F Gekeler; C Schindewolf; T Jung; K Avraham; H Behrendt; J Ring; A Zimmer; K Schughart; K Pfeffer; E Wolf; R Balling
Journal:  Nat Genet       Date:  2000-08       Impact factor: 38.330

Review 3.  Gut hormones and diabetes mellitus.

Authors:  W Creutzfeldt; M Nauck
Journal:  Diabetes Metab Rev       Date:  1992-07

Review 4.  Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide.

Authors:  H C Fehmann; R Göke; B Göke
Journal:  Endocr Rev       Date:  1995-06       Impact factor: 19.871

5.  Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling.

Authors:  A Trümper; K Trümper; H Trusheim; R Arnold; B Göke; D Hörsch
Journal:  Mol Endocrinol       Date:  2001-09

Review 6.  Large-scale N-ethyl-N-nitrosourea mutagenesis of mice--from phenotypes to genes.

Authors:  B Rathkolb; E Fuchs; H J Kolb; I Renner-Müller; O Krebs; R Balling; M Hrabé de Angelis; E Wolf
Journal:  Exp Physiol       Date:  2000-11       Impact factor: 2.969

7.  Early insulin therapy prevents beta cell loss in a mouse model for permanent neonatal diabetes (Munich Ins2(C95S)).

Authors:  S Kautz; L van Bürck; M Schuster; E Wolf; R Wanke; N Herbach
Journal:  Diabetologia       Date:  2011-11-18       Impact factor: 10.122

8.  Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

Authors:  J Andrew Pospisilik; Jennifer Martin; Timothy Doty; Jan A Ehses; Nathalie Pamir; Francis C Lynn; Shalea Piteau; Hans-Ulrich Demuth; Christopher H S McIntosh; Raymond A Pederson
Journal:  Diabetes       Date:  2003-03       Impact factor: 9.461

9.  Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase.

Authors:  Jan A Ehses; Vanbric R Casilla; Tim Doty; J Andrew Pospisilik; Kyle D Winter; Hans-Ulrich Demuth; Raymond A Pederson; Christopher H S McIntosh
Journal:  Endocrinology       Date:  2003-06-19       Impact factor: 4.736

10.  Diets influence the diabetic phenotype of transgenic mice expressing a dominant negative glucose-dependent insulinotropic polypeptide receptor (GIPRdn).

Authors:  Nadja Herbach; Burkhard Göke; Eckhard Wolf; Ruediger Wanke
Journal:  Regul Pept       Date:  2007-10-23
View more
  5 in total

1.  Down-regulation of miR-23a inhibits high glucose-induced EMT and renal fibrogenesis by up-regulation of SnoN.

Authors:  Haiping Xu; Fuyun Sun; Xiuli Li; Lina Sun
Journal:  Hum Cell       Date:  2017-07-13       Impact factor: 4.174

2.  Oxymatrine Inhibits Renal Tubular EMT Induced by High Glucose via Upregulation of SnoN and Inhibition of TGF-β1/Smad Signaling Pathway.

Authors:  Lirong Liu; Yuanyuan Wang; Rui Yan; Shuang Li; Mingjun Shi; Ying Xiao; Bing Guo
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

3.  SnoN upregulation ameliorates renal fibrosis in diabetic nephropathy.

Authors:  Lirong Liu; Mingjun Shi; Yuanyuan Wang; Changzhi Zhang; Bo Su; Ying Xiao; Bing Guo
Journal:  PLoS One       Date:  2017-03-28       Impact factor: 3.240

4.  MicroRNA‑379‑5p suppresses renal fibrosis by regulating the LIN28/let‑7 axis in diabetic nephropathy.

Authors:  Nan Li; Li-Juan Wang; Wei-Long Xu; Su Liu; Jiang-Yi Yu
Journal:  Int J Mol Med       Date:  2019-08-30       Impact factor: 4.101

5.  The proteasome inhibitor, MG132, attenuates diabetic nephropathy by inhibiting SnoN degradation in vivo and in vitro.

Authors:  Wei Huang; Chen Yang; Qinling Nan; Chenlin Gao; Hong Feng; Fang Gou; Guo Chen; Zhihong Zhang; Pijun Yan; Juan Peng; Yong Xu
Journal:  Biomed Res Int       Date:  2014-06-09       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.